Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-1500 Single Ascending Dose Study in Healthy Subjects
NCT07473752Phase 1Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TNX-1500 in autoimmune diseases and organ transplant rejection (4 arms), sponsored by Tonix Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at Day 120. Started Jul 2023; status: completed.
02
Drugs
TNX-1500
03
Conditions
autoimmune diseasesorgan transplant rejection
Beyond the preview
Go deeper on NCT07473752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473752.